Scarica l'app Stockscreener
4.46
0.89%
-0.04
Pre-mercato:
4.51
0.05
+1.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.50
Aprire:
$4.52
Volume 24 ore:
1.81M
Relative Volume:
0.75
Capitalizzazione di mercato:
$391.92M
Reddito:
$30.91M
Utile/perdita netta:
$-209.47M
Rapporto P/E:
-1.3402
EPS:
-3.3279
Flusso di cassa netto:
$-147.13M
1 W Prestazione:
+16.75%
1M Prestazione:
+20.22%
6M Prestazione:
-35.17%
1 anno Prestazione:
-7.08%
Intervallo 1D:
$4.41
$4.74
Intervallo di 1 settimana:
$3.745
$4.74
Portata 52W:
$3.43
$11.24
Verastem Inc Stock (VSTM) Company Profile
Nome
Verastem Inc
Settore
Industria
Telefono
(781) 292-4200
Indirizzo
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
4.46 | 335.68M | 30.91M | -209.47M | -147.13M | -3.3279 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-12 | Ripresa | BTIG Research | Buy |
| 2026-02-04 | Iniziato | H.C. Wainwright | Buy |
| 2025-10-16 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-04-10 | Iniziato | Jefferies | Buy |
| 2025-03-24 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-31 | Reiterato | BTIG Research | Buy |
| 2024-09-30 | Iniziato | Guggenheim | Buy |
| 2023-11-21 | Ripresa | BTIG Research | Buy |
| 2023-09-27 | Iniziato | B. Riley Securities | Buy |
| 2023-06-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-07 | Ripresa | Alliance Global Partners | Buy |
| 2022-04-29 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-04-14 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-03-09 | Iniziato | Truist | Buy |
| 2021-07-01 | Iniziato | Alliance Global Partners | Buy |
| 2021-05-24 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2019-06-20 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | Iniziato | BTIG Research | Buy |
| 2018-05-02 | Iniziato | Seaport Global Securities | Buy |
| 2018-03-08 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-13 | Iniziato | Oppenheimer | Outperform |
| 2017-03-24 | Reiterato | H.C. Wainwright | Buy |
| 2015-09-29 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | Downgrade | Jefferies | Buy → Hold |
| 2015-09-29 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | Downgrade | Mizuho | Buy → Neutral |
| 2015-09-28 | Downgrade | ROTH Capital | Buy → Neutral |
| 2015-09-09 | Iniziato | Raymond James | Strong Buy |
| 2015-05-12 | Reiterato | UBS | Buy |
| 2015-04-08 | Iniziato | H.C. Wainwright | Buy |
| 2015-01-23 | Reiterato | ROTH Capital | Buy |
| 2014-07-08 | Ripresa | Oppenheimer | Perform |
| 2014-02-11 | Iniziato | Mizuho | Buy |
Mostra tutto
Verastem Inc Borsa (VSTM) Ultime notizie
Enterprise value to EBIT forward of Verastem, Inc. – NASDAQ:VSTM - TradingView
Verastem (VSTM) Shares Encouraging Results from VS-7375 Phase 1/2 Trial - Insider Monkey
5 Best Stocks Under $10 Offering More Than 50% Upside - Insider Monkey
Verastem, Inc.(NasdaqCM: VSTM) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Verastem, Inc.(NasdaqCM: VSTM) dropped from Russell 3000 Value Benchmark - marketscreener.com
Verastem, Inc.(NasdaqCM: VSTM) dropped from Russell 3000E Value Benchmark - marketscreener.com
Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? - Stocktwits
Verastem, Inc. Actuals & Estimates (SWB:2VSA) - TradingView
Verastem, Inc. Stock Hits New 52-Week Low at $3.43 - MarketsMojo
Verastem, Inc. Actuals & Estimates (NASDAQ:VSTM) - TradingView
Price to earnings forward of Verastem, Inc. – NASDAQ:VSTM - TradingView
VSTM Forecast — Price Target — Prediction for 2027 - TradingView
VSTM Technical Analysis & Stock Price Forecast - Intellectia AI
Price to book forward of Verastem, Inc. – NASDAQ:VSTM - TradingView
Verastem (VSTM) insider sale notice: 21,492 shares reported for resale - Stock Titan
Verastem, Inc. Actuals & Estimates (GETTEX:2VSA) - TradingView
Enterprise value to revenue forward of Verastem, Inc. – GETTEX:2VSA - TradingView
2VSA Forecast — Price Target — Prediction for 2027 - TradingView
Is Verastem, Inc. (VSTM)’s KRAS-Targeted Combination Therapy a Breakthrough for Pancreatic Cancer? - Insider Monkey
A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $14 to $18 - Moomoo
Price to sales forward of Verastem, Inc. – GETTEX:2VSA - TradingView
Price to book forward of Verastem, Inc. – GETTEX:2VSA - TradingView
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Verastem (VSTM) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Verastem Inc (VSTM) CEO Dan Paterson Sells 20,871 Shares - GuruFocus
VSTM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18.00 - GuruFocus
Verastem CFO Daniel Calkins sells $17,089 in company stock By Investing.com - Investing.com Australia
Form 4 Verastem Inc For: 24 June By Investing.com - Investing.com South Africa
Verastem CEO Dan Paterson sells $87,240 in shares By Investing.com - Investing.com South Africa
Verastem CEO Dan Paterson sells $87,240 in shares - Investing.com UK
Verastem CFO Daniel Calkins sells $17,089 in company stock - Investing.com
Verastem (VSTM) CEO sells 20,871 shares to cover RSU tax withholding - Stock Titan
Verastem (NASDAQ: VSTM) CFO sells 4,089 shares to cover RSU taxes - Stock Titan
VSTM Q1 2026 Earnings: EPS Beats Estimates by 2.19% as Pre-Revenue Biotech Advances Pipeline - dars.gov.et
VSTM Reiterates by BTIG -- Price Target Maintained at $18.00 - GuruFocus
RBC Capital reiterates Verastem stock rating on G12D inhibitor potential - Investing.com
RBC Capital reiterates Verastem stock rating on G12D inhibitor potential By Investing.com - Investing.com Canada
A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $8 to $18 - Moomoo
Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101 Data for VS-7375 in KRAS G12D Mutated CancersSlideshow (NASDAQ:VSTM) 2026-06-24 - Seeking Alpha
H.C. Wainwright reiterates Verastem stock rating on drug trial data By Investing.com - Investing.com UK
VSTM Maintains Rating by Jefferies -- Price Target Lowered to $8 - GuruFocus
Verastem Inc (VSTM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Verastem (VSTM) Reports Promising Outcomes from Phase 1/2 Trial of VS-7375 - GuruFocus
Verastem Reports Positive Early Data for KRAS Cancer Drug VS-7375 - Moomoo
Verastem Advances VS-7375 with Promising Early Trial Data - TipRanks
Verastem stock falls despite early cancer drug trial data By Investing.com - Investing.com South Africa
Verastem stock falls despite early cancer drug trial data - Investing.com
Verastem posts VS-7375 data, reports anti-tumor activity at 400–900 mg QD and 93% CA19-9 drops in mPDAC - TradingView
Verastem (NASDAQ: VSTM) details VS-7375 KRAS G12D data and plans Phase 3 trials - Stock Titan
VERASTEMVS-7375 SAFETY PROFILE MAINLY LOW-GRADE GI EVENTS THAT DECREASE AFTER CYCLE 1 - Moomoo
Verastem's New Drug Shows Major Promise Against a Notorious Cancer Gene - BriefGlance
Verastem Inc Azioni (VSTM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Verastem Inc Azioni (VSTM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Paterson Dan | President and CEO |
Jun 22 '26 |
Sale |
4.18 |
20,871 |
87,241 |
591,242 |
| Calkins Daniel | Chief Financial Officer |
Jun 22 '26 |
Sale |
4.18 |
4,089 |
17,089 |
117,238 |
0.05%
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):